Hydrogen sulfide protects against IL-1β-induced inflammation and mitochondrial dysfunction-related apoptosis in chondrocytes and ameliorates osteoarthritis

J Cell Physiol. 2021 Jun;236(6):4369-4386. doi: 10.1002/jcp.30154. Epub 2020 Nov 8.

Abstract

The inflammatory environment and excessive chondrocyte apoptosis have been demonstrated to play crucial roles in the onset of osteoarthritis (OA). Hydrogen sulfide (H2 S), a gaseous signalling molecule, exerts an inhibitory effect on inflammation and apoptosis in several degenerative diseases. However, the protective effect of H2 S against OA has not been fully clarified, and its underlying mechanism should be examined further. In the current study, the role of endogenous H2 S in the pathogenesis of OA and its protective effects on interleukin (IL)-1β-induced chondrocytes were identified. Our data revealed decreased H2 S expression in both human degenerative OA cartilage tissue and IL-1β-induced chondrocytes. Pretreatment with the H2 S donor sodium hydrosulfide (NaHS) dramatically attenuated IL-1β-induced overproduction of inflammatory cytokines and improved the balance between anabolic and catabolic chondrocyte capacities, and these effects were dependent on PI3K/AKT pathway-mediated inhibition of nuclear factor kappa B (NF-κB). Moreover, mitochondrial dysfunction-related apoptosis was significantly reversed by NaHS in IL-1β-stimulated chondrocytes. Mechanistically, NaHS partially suppressed IL-1β-induced phosphorylation of the mitogen-activated protein kinase (MAPK) cascades. Furthermore, in the destabilization of the medial meniscus mouse model, OA progression was ameliorated by NaHS administration. Taken together, these results suggest that H2 S may antagonize IL-1β-induced inflammation and mitochondrial dysfunction-related apoptosis via selective suppression of the PI3K/Akt/NF-κB and MAPK signalling pathways, respectively, in chondrocytes and may be a potential therapeutic agent for the treatment of OA.

Keywords: apoptosis; chondrocytes; hydrogen sulfide; inflammation; osteoarthritis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Animals
  • Antirheumatic Agents / metabolism
  • Antirheumatic Agents / pharmacology*
  • Apoptosis / drug effects*
  • Case-Control Studies
  • Cells, Cultured
  • Chondrocytes / drug effects*
  • Chondrocytes / immunology
  • Chondrocytes / metabolism
  • Chondrocytes / pathology
  • Disease Models, Animal
  • Female
  • Humans
  • Hydrogen Sulfide / metabolism
  • Hydrogen Sulfide / pharmacology*
  • Inflammation Mediators / metabolism*
  • Interleukin-1beta / toxicity*
  • Joints / drug effects*
  • Joints / immunology
  • Joints / metabolism
  • Joints / pathology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Middle Aged
  • Mitochondria / drug effects*
  • Mitochondria / immunology
  • Mitochondria / metabolism
  • Mitochondria / pathology
  • Mitogen-Activated Protein Kinases / metabolism
  • NF-kappa B / metabolism
  • Osteoarthritis / drug therapy*
  • Osteoarthritis / immunology
  • Osteoarthritis / metabolism
  • Osteoarthritis / pathology
  • Phosphatidylinositol 3-Kinase / metabolism
  • Phosphorylation
  • Proto-Oncogene Proteins c-akt / metabolism
  • Signal Transduction
  • Sulfides / metabolism
  • Sulfides / pharmacology*

Substances

  • Antirheumatic Agents
  • IL1B protein, human
  • Inflammation Mediators
  • Interleukin-1beta
  • NF-kappa B
  • Sulfides
  • Phosphatidylinositol 3-Kinase
  • Proto-Oncogene Proteins c-akt
  • Mitogen-Activated Protein Kinases
  • sodium bisulfide
  • Hydrogen Sulfide